Coherus Biosciences Inc

NASDAQ:CHRS   3:59:52 PM EDT
16.81
+0.13 (+0.78%)
Products, Regulatory

Positive Results Of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate Chs-201 Presented At Retina Society Annual Scientific Meeting

Published: 10/04/2021 12:16 GMT
Coherus Biosciences Inc (CHRS) - Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate Chs-201 to Reference Product Lucentis® (ranibizumab) in the Treatment of Neovascular (wet) Age-related Macular Degeneration (namd) Presented at Retina Society Annual Scientific Meeting.
Coherus Biosciences Inc - Columbus-amd Study Demonstrated Similarity of Chs-201 and Reference Product Lucentis in Terms of Clinical Efficacy.